Wedbush


Polypore International: We Are Cautious On PolyPore’s Prospect For A Near-Term Rebound, Says Wedbush

In a research note released yesterday, Wedbush analyst Craig Irwin maintained a Neutral rating on Polypore International (PPO) with a price target of $38, …

Wedbush Maintains Neutral On Lumber Liquidators; Raises Questions About The Company’s Future

In a research note reported yesterday, Wedbush analyst Seth Basham maintained a Neutral rating on Lumber Liquidators (LL) and lowered his price target to $67 …

Wedbush Reiterates Neutral On PetSmart As Potential Upside Largely Priced Into Shares

In a research note published yesterday, Wedbush analyst Seth Basham reiterated a Neutral rating on PetSmart (PETM) with a $64 price target, which suggests …

Wedbush Reiterates Outperform On Lexicon Following Funding Support From JDRF

In a research report released yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target, …

Wedbush Reiterates Outperform On Lexicon Following Appointment Of New CEO

In a research report published yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target …

Wedbush Reiterates An Outperform On Anacor Following FDA Approval Of Kerydin

In a research note released yesterday, Wedbush analyst David Nierengarten reiterated an Outperform rating on Anacor Pharmaceuticals (ANAC) with a price target of …

Wedbush Reiterates Neutral Rating On PetSmart As Competition Increases And Consumer Behavior Changes

In a research note released Monday, Wedbush analyst Seth Basham maintained a Neutral rating on PetSmart (PETM) and raised his price target to …

Wedbush Reiterates Outperform On Xoma Following An Update On Phase 3 Trial

In a research note issued Tuesday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on XOMA Corporation (XOMA) and a price target of $14.00, following the news that the last exacerbation event for …

Analyst Vs. Analyst: Herbalife Edition – Who Do You Side With?

Today we are going to be having our first analyst versus analyst special, featuring Wedbush analyst, Rommel Dionisio versus Argus analyst John Staszak. Today …

Checks Suggest Illumina Has Won An Exclusive Competitive Contract with Progenity, Says Wedbush

In a research note issued today, Wedbush analyst Zarak Khurshid reiterated coverage with a “Neutral” rating on Illumina Inc. (ILMN) and a price target of $155.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts